Co-Authors
This is a "connection" page, showing publications co-authored by Lauge Østergaard and Ole Søgaard.
Connection Strength
0.650
-
Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin. AIDS. 2018 07 31; 32(12):1729-1731.
Score: 0.195
-
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017 Jun 15; 64(12):1686-1695.
Score: 0.180
-
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021 Feb; 64:103230.
Score: 0.058
-
Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. AIDS. 2018 08 24; 32(13):1793-1802.
Score: 0.049
-
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses. mSphere. 2018 Jan-Feb; 3(1).
Score: 0.047
-
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight. 2017 Aug 17; 2(16).
Score: 0.046
-
Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. AIDS. 2017 03 27; 31(6):771-779.
Score: 0.044
-
Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice. Infect Immun. 2012 May; 80(5):1744-52.
Score: 0.031